Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension

Boehringer Ingelheim

Status and phase: Completed; Phase 3

Conditions: Hypertension

Treatments: Drug: High dose of telmisartan; Drug: Low dose of losartan; Drug: Low dose of telmisartan; Drug: High dose of losartan

Study type: Interventional

Funder types: Industry

Identifiers

NCT02269176

502.365

Details and patient eligibility

About

Using Losartan as a comparator, to evaluate the efficacy and safety of telmisartan in the treatment of the mild to moderate primary hypertension patients in China

Enrollment: 330 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Mild to moderate primary hypertension, the mean sitting valley value of diastolic blood pressure (DBP) ≥ 95 and < 110 mmHg, and the mean sitting valley value of systolic blood pressure (SBP) < 180 mmHg

Exclusion criteria

• Not specified

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

330 participants in 2 patient groups

Telmisartan

Experimental group

Description:

Low dose of telmisartan, uptitrated to high dose in case no sufficient effect is observered

Treatment:

Drug: High dose of telmisartan

Drug: Low dose of telmisartan

Losartan

Active Comparator group

Description:

Low dose of losartan, uptitrated to high dose in case no sufficient effect is observered

Treatment:

Drug: High dose of losartan

Drug: Low dose of losartan